Platelet Count

• 

  Subject Areas on Research

  • A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. 
  • A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. 
  • A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. 
  • A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. 
  • A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. 
  • A multicenter mortality prediction model for patients receiving prolonged mechanical ventilation. 
  • A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. 
  • A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. 
  • A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. 
  • A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group. 
  • A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. 
  • Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. 
  • Alloimmune thrombocytopenia may be associated with systemic disease. 
  • Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. 
  • Automated platelet counters: a comparative evaluation of latest instrumentation. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. 
  • Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. 
  • Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. 
  • Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. 
  • Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. 
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. 
  • Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. 
  • Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab')2 versus Fab antivenom trial. 
  • Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. 
  • Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. 
  • Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. 
  • Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. 
  • Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. 
  • Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. 
  • Diagnostic Algorithm for Patients With Suspected Giant Cell Arteritis. 
  • Differential platelet levels affect response to taxane-based therapy in ovarian cancer. 
  • Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. 
  • Distinguishing Arterial Ischemic Stroke From Hypoxic-Ischemic Encephalopathy in the Neonate at Birth. 
  • Does maternal platelet-associated or platelet-bindable IgG correlate with levels in umbilical cord blood or colostrum during normal pregnancy? 
  • Does this patient with liver disease have cirrhosis? 
  • Dose of prophylactic platelet transfusions and prevention of hemorrhage. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. 
  • Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 
  • Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation. 
  • Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. 
  • Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. 
  • Factors and inhibitors of blood coagulation and fibrinolysis in acute nonlymphoblastic leukaemia. 
  • Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. 
  • Genome-wide Association Study of Platelet Count Identifies Ancestry-Specific Loci in Hispanic/Latino Americans. 
  • Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. 
  • Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. 
  • HIV infection in a defined population of Swedish haemophiliacs. 
  • HIV-1-associated thrombocytopenia. The role of splenectomy. 
  • Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. 
  • Hematologic indexes in men attending an infertility clinic. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin-induced thrombocytopenia and cardiac surgery. 
  • Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. 
  • Heparin-induced thrombocytopenia, a prothrombotic disease. 
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura. 
  • Hostility and platelet reactivity in individuals without a history of cardiovascular disease events. 
  • How Low Is Too Low? Postpartum Hemorrhage Risk among Women with Thrombocytopenia. 
  • Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. 
  • Idiopathic thrombocytopenic purpura: mother and neonate. 
  • Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? 
  • Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • In vivo evaluations of a new thromboresistant polyurethane for artificial heart blood pumps. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. 
  • Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. 
  • Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. 
  • Infectious and bleeding complications in patients with glycogenosis Ib. 
  • Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. 
  • Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. 
  • Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. 
  • Interaction of ibuprofen and warfarin on primary haemostasis. 
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. 
  • Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study. 
  • Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. 
  • Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. 
  • Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. 
  • Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. 
  • Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. 
  • Low-dose endotoxin elicits variability in the inflammatory response in healthy volunteers. 
  • Magnetic resonance imaging and hepatic hemodynamics: correlation with metabolic function in liver transplantation candidates. 
  • Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia. 
  • Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. 
  • Natural history of nonimmune-mediated thrombocytopenia and acute kidney injury in pediatric open-heart surgery. 
  • Neurologic manifestations of essential thrombocythemia. 
  • New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. 
  • Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension. 
  • Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. 
  • Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Optimization of a murine immunization model for study of PF4/heparin antibodies. 
  • Pancreatic islet cell carcinoma associated with multiple hormone secretion and pancytopenia. Evidence of a serum factor suppressing hematopoiesis. 
  • Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. 
  • Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state. 
  • Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. 
  • Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis. 
  • Pharmacokinetic and phase I evaluation of carboplatin in dogs. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Plasma thrombopoietic activity in humans with normal and abnormal platelet counts. 
  • Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. 
  • Platelet Counts and Postoperative Stroke After Coronary Artery Bypass Grafting Surgery. 
  • Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet antibody in prolonged remission of childhood idiopathic thrombocytopenic purpura. 
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. 
  • Platelet count in deep saturation diving. 
  • Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
  • Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. 
  • Platelet-mediated thrombolysis in patients with δ-storage pool deficiency: a thrombelastographic analysis. 
  • Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. 
  • Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. 
  • Prednisone-responsive aplastic anemia associated with T-lymphocyte proliferation. 
  • Preoperative Platelet Count Predicts Lower Extremity Free Flap Thrombosis: A Multi-Institutional Experience. 
  • Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. 
  • Prognostic factors and treatment effects on survival in erythroleukemia: a retrospective study of 134 cases. 
  • Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura. 
  • Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. 
  • Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 
  • Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study. 
  • Recognition of early mortality in multiple myeloma by a prediction matrix. 
  • Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. 
  • Reduction in blood transfusion in a cohort of infants having cardiac surgery with cardiopulmonary bypass after instituting a goal-directed transfusion policy. 
  • Renal dysfunction in allogeneic hematopoietic cell transplantation. 
  • Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Secondary failure of platelet recovery after hematopoietic stem cell transplantation. 
  • Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. 
  • Sirolimus monotherapy following Campath-1H induction. 
  • Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results. 
  • Spuriously elevated platelet counts due to microspherocytosis. 
  • The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. 
  • The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The effects of total lymphoid irradiation upon corneal vascularization in the rat following chemical cautery. 
  • The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. 
  • The influence of red wine or white wine intake on platelet function and viscoelastic property of blood in volunteers. 
  • The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. 
  • Therapeutic angiography in renal transplant complications. 
  • Thrombocytopenia in allogeneic peripheral blood stem cell collections. 
  • Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. 
  • United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. 
  • Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer. 
  • Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. 
  • Warfarin therapy does not increase bleeding in patients undergoing heart transplantation. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • Whole blood serotonin relates to violence in an epidemiological study. 
  • Whole body hyperthermia and heat-sensitizing drugs: a pilot study in canine lymphoproliferative disease. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • Moon, Richard Edward, Professor of Anesthesiology, Medicine, Pulmonary, Allergy, and Critical Care Medicine